S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Forecast, Price & News

$8.05
-0.30 (-3.59%)
(As of 10/2/2023 ET)
Compare
Today's Range
$7.96
$8.39
50-Day Range
$8.05
$13.50
52-Week Range
$5.46
$14.55
Volume
5.83 million shs
Average Volume
3.90 million shs
Market Capitalization
$2.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.10

Pacific Biosciences of California MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
62.7% Upside
$13.10 Price Target
Short Interest
Bearish
13.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Pacific Biosciences of California in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.18) to ($1.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

836th out of 975 stocks

Analytical Instruments Industry

25th out of 29 stocks


PACB stock logo

About Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Price History

PACB Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
5 Analysts Have This to Say About Pacific Biosciences
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
PacBio Announces PacBio Capital
Cathie Wood's Buying These 3 Stocks Hand Over Fist
Goldman Sachs Keeps Their Buy Rating on Pacific Biosciences (PACB)
Time to Nail Down Profits in One of My Top Picks
The Latest Analyst Ratings for Pacific Biosciences
Barclays Keeps Their Hold Rating on Pacific Biosciences (PACB)
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Company Calendar

Last Earnings
8/02/2023
Today
10/03/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
769
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$13.10
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+62.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-314,250,000.00
Net Margins
-218.43%
Pretax Margin
-218.43%

Debt

Sales & Book Value

Annual Sales
$128.30 million
Book Value
$2.49 per share

Miscellaneous

Free Float
247,050,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
1.72

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $1.1M
  • Ms. Susan G. KimMs. Susan G. Kim (Age 47)
    Chief Financial Officer
    Comp: $564.87k
  • Mr. Mark Van Oene (Age 50)
    Chief Operating Officer
    Comp: $772.11k
  • Mr. Jeff Eidel (Age 46)
    Chief Commercial Officer
    Comp: $435.62k
  • Dr. Stephen Turner (Age 55)
    Co-Founder & CTO
  • Ms. Michele Farmer CPA (Age 43)
    VP & Chief Accounting Officer
  • Dr. Jonas Korlach Ph.D.
    Chief Scientific Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., Gen. Counsel & Corp. Sec.
  • Ms. Natalie Welch
    Chief People Officer













PACB Stock - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price forecast for 2023?

9 brokerages have issued 12-month price targets for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $9.00 to $17.00. On average, they predict the company's stock price to reach $13.10 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2023?

Pacific Biosciences of California's stock was trading at $8.18 at the beginning of 2023. Since then, PACB stock has decreased by 1.6% and is now trading at $8.05.
View the best growth stocks for 2023 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our PACB earnings forecast
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.06. The biotechnology company had revenue of $47.57 million for the quarter, compared to analyst estimates of $40.12 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 46.47% and a negative net margin of 218.43%. Pacific Biosciences of California's revenue was up 34.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.34) earnings per share.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $8.05.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.02 billion and generates $128.30 million in revenue each year. The biotechnology company earns $-314,250,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

The company employs 769 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.

This page (NASDAQ:PACB) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -